Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity? - Wikidata - awgldk - TriplyDB

Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?

Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?

http://www.wikidata.org/entity/Q37826199

about

Tetraspecific ligand for tumor-targeted delivery of nanomaterials.Advances in first-line treatment for patients with HER-2+ metastatic breast cancer.

P2860

Q34380877-8349DEB3-6C47-4152-A6E5-C645FE1B2664 Q35989963-3DF718D8-0598-4AFA-9EE4-5E9A722392EB

P2860

Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?

http://www.wikidata.org/entity/Q37826199

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 January 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Hitting multiple targets in HE ...... le or therapeutic opportunity?

@en

Hitting multiple targets in HE ...... le or therapeutic opportunity?

@nl

type

label

Hitting multiple targets in HE ...... le or therapeutic opportunity?

@en

Hitting multiple targets in HE ...... le or therapeutic opportunity?

@nl

prefLabel

Hitting multiple targets in HE ...... le or therapeutic opportunity?

@en

Hitting multiple targets in HE ...... le or therapeutic opportunity?

@nl

P1433

Q37826199-420B2CCB-8FC2-487E-B58E-272086C8C25F

P1476

Q37826199-3C2228DA-BF55-4ADE-A8F7-7309A70B8C38

P2093

Q37826199-1E29526B-4695-4FA2-9CC6-0B83C6583F27

Q37826199-8590DAF3-2FC4-4814-B931-36FFD7E86A0B

Q37826199-9C61F4E2-FFBE-490F-9CA3-94E5E636A712

Q37826199-D756DEC7-4E8D-404D-B431-43E426B3422E

Q37826199-FB03EBD4-4A86-44EB-A211-4ED1712A4A0F

P2860

Q37826199-02BD7358-E0DC-471E-B73B-6CDC1E1D4AC1

Q37826199-0B0BF1A7-46A0-4CB1-A97E-8DBB05CD6D88

Q37826199-0E18BBC6-5468-408F-8345-27AB964106DB

Q37826199-10ACDED3-D6A9-49D4-BFEF-0708CC135BF6

Q37826199-12E45920-9951-40E0-9BAB-957A61242BEE

Q37826199-159EE0C0-B0A8-4156-8FC4-10EC8AB33585

Q37826199-16A40257-7DA5-409A-A967-C074473F2AEA

Q37826199-1A1E0D6D-13DE-4950-BB75-D69B1EF0406F

Q37826199-1D1DD953-0823-45F4-8E65-031AD347CDDD

Q37826199-1FEE360F-C248-45A6-BA7F-022BA9FA1C6A

P304

Q37826199-08DDE7CB-A2A0-4D12-812B-468204DE2E0D

P31

Q37826199-CF0BCA84-6432-486C-AD0A-C8F848A8B545

Q37826199-add10cb3-0689-4068-9c2f-b9fa8c35c79d

P356

Q37826199-72832191-7834-41D4-A529-DFF7DECDA90D

P407

Q37826199-9B40CEC7-4F2A-4FBC-9B2F-BF50E0BD888D

P433

Q37826199-1F2D046D-D7B1-4269-B440-7188146D004A

P478

Q37826199-FF28444E-E7F6-48E6-99EF-94575E825901

P50

Q37826199-0EBC1168-5E21-4B81-B555-884C8554D7EE

Q37826199-285FCAD9-A61A-4896-B67D-63AC0974DC3D

P577

Q37826199-8CD997F9-C167-4FE7-9FE9-05B483381186

P698

Q37826199-955803BB-3478-4D6C-B4C2-815604623DB3

P356

14656566.2011.525218

P1433

Expert Opinion on Pharmacotherapy

P1476

Hitting multiple targets in HE ...... le or therapeutic opportunity?

@en

P2093

Andrea Milani

http://www.w3.org/2001/XMLSchema#string

Elena Geuna

http://www.w3.org/2001/XMLSchema#string

Filippo Montemurro

http://www.w3.org/2001/XMLSchema#string

Stefania Redana

http://www.w3.org/2001/XMLSchema#string

Valentina Rossi

http://www.w3.org/2001/XMLSchema#string

P2860

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

Cell signaling by receptor tyrosine kinases

P304

549-565

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2011.525218

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Giorgio Valabrega

P577

2011-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21208143

http://www.w3.org/2001/XMLSchema#string